Related Experiment Videos
Treatment of acute myocardial infarction with cardiogenic shock using left ventricular assist device
Insights
Left ventricular assist device (LVAD) therapy can aid recovery in cardiogenic shock patients post-acute myocardial infarction (AMI). Early LVAD application is crucial to prevent irreversible organ damage and improve survival rates.
Area of Science:
- Cardiology
- Mechanical Circulatory Support
Background:
- Cardiogenic shock following acute myocardial infarction (AMI) presents a critical challenge.
- Left ventricular assist devices (LVADs) offer a potential therapeutic option.
Purpose of the Study:
- To evaluate the outcomes of LVAD treatment in cardiogenic shock patients.
- To assess the impact of concurrent procedures like aorto-coronary bypass grafting (ACBG) on LVAD therapy.
Main Methods:
- Retrospective analysis of ten cardiogenic shock patients treated with LVAD post-AMI.
- Patients categorized into three groups: ventricular septal perforation, pre-LVAD ACBG, and no ACBG.
- Assessment of LVAD support, cardiac recovery, and patient survival.
Main Results:
- Seventy percent of patients were successfully weaned from LVAD.
- Outcomes varied by group, with challenges including multiple organ failure and hemorrhagic necrosis.
- Early LVAD application appeared critical, as prolonged low output pre-LVAD was linked to mortality.
Conclusions:
- LVAD therapy can be effective in selected cardiogenic shock patients.
- Timely LVAD intervention before irreversible organ damage is essential.
- Integration of LVAD into standard AMI treatment protocols warrants further investigation.
Abstract:
We have treated ten cardiogenic shock patients after acute myocardial infarction (AMI) with a left ventricular assist device (LVAD). These patients were later divided into three groups: the first group with ventricular septal perforation, the second with aorto-coronary bypass grafting (ACBG) before LVAD implantation and the third group without ACBG. LVAD maintained the systemic circulation in each group, and cardiac function recovered enough to remove LVAD in 70% of the total patients. Two of three patients in the first group were discharged from hospital. Two weaned cases in the second group died of multiple organ failure and one was discharged, and hemorrhagic necrosis was seen in the bypassed area of the myocardium. One patient of the third group could not be weaned from LVAD because of respiratory failure though his heart function began to recover. Another case in the third group underwent bypass grafting after removal of LVAD. However ACBG surgery should be done very carefully because a patient in shock is occasionally intolerant to major surgery. In all groups, the major cause of death was multiple organ failure which was probably caused by the prolonged low output condition prior to LVAD application. In the light of this experience, it appears that LVAD should be applied before irreversible damage occurs to major organs, including the heart itself. To ensure the timely application of LVAD, some way must be found to introduce systematic application of LVAD into the normal course of AMI treatment.